Quest Diagnostics Inc (DGX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.76%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.76% | Share-based compensation / revenue. Period ending 2026-06-30. $88.00M ÷ $11.56B × 100 ≈ 0.76% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 11.56B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 88.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.63B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.56B | $88.00M | $1.63B | (m) | (m) | 0.76% | (m) | (m) |
| 2026-03-31 | (m) | $11.28B | $86.00M | $1.61B | (m) | (m) | 0.76% | (m) | (m) |
| 2025-12-31 | (m) | $11.04B | $88.00M | $1.56B | (m) | (m) | 0.80% | (m) | (m) |
| 2025-09-30 | (m) | $10.85B | $90.00M | $1.53B | (m) | (m) | 0.83% | (m) | (m) |
| 2025-06-30 | (m) | $10.52B | $89.00M | $1.48B | (m) | (m) | 0.85% | (m) | (m) |
| 2025-03-31 | (m) | $10.16B | $88.00M | $1.39B | (m) | (m) | 0.87% | (m) | (m) |
| 2024-12-31 | (m) | $9.87B | $88.00M | $1.35B | (m) | (m) | 0.89% | (m) | (m) |
| 2024-09-30 | (m) | $9.54B | $80.00M | $1.25B | (m) | (m) | 0.84% | (m) | (m) |
| 2024-06-30 | (m) | $9.35B | $79.00M | $1.26B | $183.00M | (m) | 0.85% | 6.91× | Reported |
| 2024-03-31 | (m) | $9.29B | $75.00M | $1.26B | $175.00M | (m) | 0.81% | 7.18× | Reported |
| 2023-12-31 | (m) | $9.25B | $77.00M | $1.26B | $163.00M | (m) | 0.83% | 7.74× | Reported |
| 2023-09-30 | (m) | $9.30B | $80.00M | $1.13B | $153.00M | (m) | 0.86% | 7.39× | Reported |
| 2023-06-30 | (m) | $9.49B | $80.00M | $1.18B | $149.00M | (m) | 0.84% | 7.92× | Reported |
| 2023-03-31 | (m) | $9.60B | $83.00M | $1.22B | $148.00M | (m) | 0.86% | 8.24× | Reported |
| 2022-12-31 | (m) | $9.88B | $77.00M | $1.43B | $148.00M | (m) | 0.78% | 9.65× | Reported |
| 2022-09-30 | (m) | $10.29B | $74.00M | $1.83B | $150.00M | (m) | 0.72% | 12.19× | Reported |
| 2022-06-30 | (m) | $10.58B | $77.00M | $2.09B | $151.00M | (m) | 0.73% | 13.83× | Reported |
| 2022-03-31 | (m) | $10.68B | $79.00M | $2.23B | $151.00M | (m) | 0.74% | 14.79× | Reported |
| 2021-12-31 | (m) | $10.79B | $79.00M | $2.38B | $152.00M | (m) | 0.73% | 15.66× | Reported |
| 2021-09-30 | (m) | $11.05B | $94.00M | $2.64B | $154.00M | (m) | 0.85% | 17.14× | Reported |
| 2021-06-30 | (m) | $11.06B | $105.00M | $2.71B | $158.00M | (m) | 0.95% | 17.13× | Reported |
| 2021-03-31 | (m) | $10.34B | $101.00M | $2.46B | $162.00M | (m) | 0.98% | 15.16× | Reported |
| 2020-12-31 | (m) | $9.44B | $97.00M | $1.97B | $166.00M | (m) | 1.03% | 11.87× | Reported |
| 2020-09-30 | (m) | $8.36B | $75.00M | $1.54B | $170.00M | (m) | 0.90% | 9.05× | Reported |
| 2020-06-30 | (m) | $7.53B | $55.00M | $1.13B | $173.00M | (m) | 0.73% | 6.55× | Reported |
| 2020-03-31 | (m) | $7.66B | $53.00M | $1.16B | $177.00M | (m) | 0.69% | 6.54× | Reported |
| 2019-12-31 | (m) | $7.73B | $56.00M | $1.23B | $180.00M | (m) | 0.72% | 6.84× | Reported |
| 2019-09-30 | (m) | $7.64B | $52.00M | $1.09B | $179.00M | (m) | 0.68% | 6.08× | Reported |
| 2019-06-30 | (m) | $7.57B | $59.00M | $1.08B | $176.00M | (m) | 0.78% | 6.13× | Reported |
| 2019-03-31 | (m) | $7.54B | $59.00M | $1.08B | $173.00M | (m) | 0.78% | 6.23× | Reported |
| 2018-12-31 | (m) | $7.53B | $61.00M | $1.10B | $169.00M | (m) | 0.81% | 6.51× | Reported |
| 2018-09-30 | (m) | $7.86B | $78.00M | $1.15B | $165.00M | (m) | 0.99% | 6.97× | Reported |
| 2018-06-30 | (m) | $7.83B | $76.00M | $1.14B | $162.00M | (m) | 0.97% | 7.06× | Reported |
| 2018-03-31 | (m) | $7.78B | $81.00M | $1.16B | $157.00M | (m) | 1.04% | 7.38× | Reported |
| 2017-12-31 | (m) | $7.71B | $79.00M | $1.17B | $153.00M | (m) | 1.02% | 7.61× | Reported |
| 2017-09-30 | (m) | $7.63B | $71.00M | $1.17B | $150.00M | (m) | 0.93% | 7.81× | Reported |
| 2017-06-30 | (m) | $7.59B | $70.00M | $1.20B | $148.00M | (m) | 0.92% | 8.08× | Reported |
| 2017-03-31 | (m) | $7.55B | $68.00M | $1.30B | $145.00M | (m) | 0.90% | 8.96× | Reported |
| 2016-12-31 | (m) | $7.51B | $69.00M | $1.28B | $144.00M | (m) | 0.92% | 8.87× | Reported |
| 2016-09-30 | (m) | $7.50B | $65.00M | $1.24B | (m) | (m) | 0.87% | (m) | (m) |
| 2016-06-30 | (m) | $7.50B | $61.00M | $1.55B | (m) | (m) | 0.81% | (m) | (m) |
| 2016-03-31 | (m) | $7.52B | $58.00M | $1.43B | (m) | (m) | 0.77% | (m) | (m) |
| 2015-12-31 | (m) | $7.49B | $52.00M | $1.40B | (m) | (m) | 0.69% | (m) | (m) |
| 2015-09-30 | (m) | $7.53B | $52.00M | $1.42B | (m) | (m) | 0.69% | (m) | (m) |
| 2015-06-30 | (m) | $7.55B | $53.00M | $1.04B | (m) | (m) | 0.70% | (m) | (m) |
| 2015-03-31 | (m) | $7.53B | $51.00M | $1.00B | (m) | (m) | 0.68% | (m) | (m) |
| 2014-12-31 | (m) | $7.43B | $51.00M | $983.00M | (m) | (m) | 0.69% | (m) | (m) |
| 2014-09-30 | (m) | $7.31B | $42.00M | $996.00M | (m) | (m) | 0.57% | (m) | (m) |
| 2014-06-30 | (m) | $7.19B | $36.00M | $1.43B | (m) | (m) | 0.50% | (m) | (m) |
| 2014-03-31 | (m) | $7.11B | $35.00M | $1.46B | (m) | (m) | 0.49% | (m) | (m) |
| 2013-12-31 | (m) | $7.15B | $28.00M | $1.48B | (m) | (m) | 0.39% | (m) | (m) |
| 2013-09-30 | (m) | $7.16B | $31.35M | $1.47B | (m) | (m) | 0.44% | (m) | (m) |
| 2013-06-30 | (m) | $7.20B | $32.67M | $1.09B | (m) | (m) | 0.45% | (m) | (m) |
| 2013-03-31 | (m) | $7.26B | $35.28M | $1.13B | (m) | (m) | 0.49% | (m) | (m) |
| 2012-12-31 | (m) | $7.38B | $50.33M | $1.20B | (m) | (m) | 0.68% | (m) | (m) |
| 2012-09-30 | (m) | $7.57B | $64.20M | $1.27B | $171.09M | (m) | 0.85% | 7.41× | Reported |
| 2012-06-30 | (m) | $7.63B | $70.89M | $1.28B | $173.47M | (m) | 0.93% | 7.39× | Reported |
| 2012-03-31 | (m) | $7.63B | $73.03M | $1.26B | $178.06M | (m) | 0.96% | 7.10× | Reported |
| 2011-12-31 | (m) | $7.51B | $71.91M | $995.05M | $173.35M | (m) | 0.96% | 5.74× | Reported |
| 2011-09-30 | (m) | $7.46B | $59.67M | $964.08M | $-167.43M | (m) | 0.80% | (m) | Reported |
| 2011-06-30 | (m) | $7.41B | $60.54M | $978.89M | $-159.84M | (m) | 0.82% | (m) | Reported |
| 2011-03-31 | (m) | $7.38B | $61.74M | $1.03B | $-149.25M | (m) | 0.84% | (m) | Reported |
| 2010-12-31 | (m) | $7.37B | $53.93M | $1.30B | $-147.50M | (m) | 0.73% | (m) | Reported |
| 2010-09-30 | (m) | $7.39B | $66.77M | $1.33B | (m) | (m) | 0.90% | (m) | (m) |
| 2010-06-30 | (m) | $7.43B | $70.47M | $1.34B | (m) | (m) | 0.95% | (m) | (m) |
| 2010-03-31 | (m) | $7.45B | $72.09M | $1.34B | (m) | (m) | 0.97% | (m) | (m) |
| 2009-12-31 | (m) | $7.46B | $75.06M | $1.36B | (m) | (m) | 1.01% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $7.25B | $70.58M | $1.22B | (m) | (m) | 0.97% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $6.70B | $56.85M | $1.09B | (m) | (m) | 0.85% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |